Current stock page

Stock Analysis

Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis

Syndax Pharmaceuticals, Inc. (SNDX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

SNDX Stock Analysis Summary

Syndax Pharmaceuticals, Inc. (SNDX) currently has an AIQ Score of 43/100, indicating a bearish setup. Quality is the strongest factor at 66/100. Momentum is the weakest current factor at 14/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

SNDX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$9.45
AIQ Score43/100
Overall ViewBearish
Technical Analysis ConsensusStrong Sell
Market Cap$848.51M
P/E Ratio (TTM)-3.99
Forward P/E—
EPS (Q3 FY2026)-$0.55
Revenue (Q3 FY2026)$83.3M
Dividend Yield (TTM)0.00%
Beta0.77
Volume3.18M
52-week range$9.11-$25.59
RSI 1426.22
50-Day SMA$15.27
200-Day SMA$19.72
Analyst Price Target$36.75
Next EarningsFeb 25, 2027
As of Nov 13, 2026 · Market close

SNDXSyndax Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$9.45−$0.09 (−0.94%)

Latest quote

  • Momentum
    14
  • Value
    64
  • Quality
    66
  • Risk resilience
    37
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

SNDX Stock Analysis Summary

Syndax Pharmaceuticals, Inc. (SNDX) currently has an AIQ Score of 43/100, indicating a bearish setup. Quality is the strongest factor at 66/100. Momentum is the weakest current factor at 14/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, SNDX has AIQ Score of 43/100 with Quality base of 66/100 and fading Momentum at 14/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (66/100) leads while Momentum (14/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.94% stock move · SNDX classified in Biotechnology.

Current Evidence

BearishSNDX is in a bearish AIQ regime; Quality is the strongest visible factor at 66/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is SNDX Bullish or Bearish Right Now?

SNDX currently has a bearish overall setup. Quality is the strongest factor at 66/100, while Momentum is weakest at 14/100. The current evidence suggests a bearish setup.

Bull Case
  • - Quality is supportive at 66/100.
  • - Analyst target implies +288.89% upside from the latest quote.
Bear Case
  • - Momentum is weak at 14/100.
  • - Risk Resilience is weak at 37/100.
  • - Price is -52.08% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (37 vs 6).

Current Consensus

SNDX's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 3 neutral, and 37 sell votes. SNDX's 14-day RSI is 26.22, which places the stock in an oversold momentum range. SNDX's beta is 0.77, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in SNDX?

The largest recent change in SNDX is Momentum moving down by 6.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
-1.0
Momentum
-6.0
Quality
+1.0
Risk
+1.0

What Would Change the SNDX Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

SNDX Decision Framework

Public evidence layers, setup checks, and risk context for Syndax Pharmaceuticals, Inc..

Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis

Syndax Pharmaceuticals, Inc. has an AIQ Score of 43/100 in a Bearish regime. Quality is strongest at 66/100. Beta is 0.77, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextSNDX is in a Bearish AIQ regime with score 43/100.
Signal ConflictThe primary conflict is that quality leads at 66/100 while momentum lags at 14/100.
Factor EvidenceMomentum 14/100 · Value 64/100 · Quality 66/100 · Risk 37/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 66/100.

TimingFail

Momentum is 14/100 and RSI (14) is 26.2.

Regime fitFail

SNDX is in a Bearish regime at 43/100.

Risk controlFail

Risk factor is 37/100 with beta 0.77 and annual volatility 57.16%.

ConflictWait

Current conflict: quality leads at 66/100 while momentum lags at 14/100.

AIQ Score
43/100
Price
$9.45
Beta
0.77
RSI (14)
26.2

SNDX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

SNDX Fundamentals

SNDX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$83.3M
Net income
-$49.43M
Free cash flow
-$27.25M
View full SNDX fundamental analysis

SNDX Technical Analysis

SNDX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
26.22
Price vs SMA-50
-38.13%
View full SNDX technical analysis

SNDX Stock Catalysts

Track SNDX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 25, 2027
Analyst target
$36.75
News items
2
View SNDX earnings and stock catalysts

SNDX Dividend Analysis

SNDX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View SNDX dividend history and analysis

SNDX Financial Data

SNDX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$83.3M
EPS
-$0.55
Periods
8
View SNDX financials

SNDX Risk Analysis

SNDX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.77
Risk score
37/100
1Y volatility
57.16%
View SNDX risk analysis

SNDX Stock News

SNDX stock news, market tone, recent headlines, and catalyst context.

News items
2
Updated
Nov 15, 2026
Sentiment
—
Read SNDX stock news

SNDX vs Biotechnology Peers

Current peer cohort: SNDX · SRRK · STOK · SYRE · TARS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
SNDX
Current stock
43/10064/10014/10037/100-0.7657.16%Current
SRRK
Scholar Rock Holding Corporation
39/100—54/10052/1000.8457.45%SNDX vs SRRK
STOK
Stoke Therapeutics, Inc.
42/10022/10047/10059/1000.2353.19%SNDX vs STOK
SYRE
Spyre Therapeutics, Inc.
64/10044/10081/10053/1002.5766.66%SNDX vs SYRE
TARS
Tarsus Pharmaceuticals, Inc.
65/10075/10076/10059/1000.3645.02%SNDX vs TARS
Pairwise Compare links: SRRK · STOK · SYRE · TARSSNDX vs SRRKSNDX vs STOKSNDX vs SYRESNDX vs TARSCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a SNDX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for SNDX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-3.99
As of Nov 13, 2026
Revenue growth
81.59%
Gross margin
93.69%
Current debt / equity
-34.31
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$83.3M
Quarter net income
-$49.43M
Quarter free cash flow
-$27.25M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Bearish
RSI 14
26.22
MACD
-1.75

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
37/100
Beta
0.77
Annual volatility
57.16%
Max drawdown
-62.74%

SNDX Stock FAQ

What is SNDX stock price today?

Syndax Pharmaceuticals, Inc.'s current stock price is $9.45. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is SNDX bullish or bearish right now?

SNDX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is SNDX's market cap?

SNDX's market cap is $848.51M based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is SNDX's current P/E ratio?

SNDX's current P/E ratio is -3.99 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is SNDX's RSI?

SNDX's 14-day RSI is 26.22 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is SNDX above its 50-day and 200-day moving averages?

SNDX is -38.13% from its 50-day SMA and -52.08% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is SNDX's next earnings date?

SNDX's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does SNDX pay a dividend?

SNDX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.